ERBB2 and neoplasm: In another study, Hanauer et al. [39], using a bispecific oncolytic MeV, with both HER2 and EpCAM as target receptors, demonstrated a significantly enhanced lysis of tumour cells in xenograft mice, highlighting the superiority of bispecific against monospecific oncolytic viruses [39].